PDS Biotechnology Corporation announced the publication of preclinical research and a patent granted by the United States Patent and Trademark Office (USPTO) that strengthen the foundation of the Company?s infectious disease vaccine platform Infectimune®. Preclinical research published in Vaccines demonstrated that the recombinant protein influenza vaccine Flublok® combined with Infectimune® (R-DOTAP) significantly promoted improved quantity and quality of potent multifunctional CD4 T cells when compared to infectious disease adjuvants. The research concluded that Infectimune® is a leading candidate for use in the next generation of preventive vaccines that may provide more effective and broader protection than current vaccines allow.

Infectimune® is being used in PDS0202, the Company?s universal influenza vaccine intended to provide broad protection against multiple flu strains.